Clinical trials: Hip OA
Localized Primary Osteoarthritis of Hip, Localized Primary Osteoarthritis of Knee
Phase III Study of CG100649 in Osteoarthritis Patients
6-week Efficacy Study The objective of this study is to prove the safety and non-inferiority of analgesic efficacy of CG100649 2 mg vs. celecoxib 200 mg, and analgesic superiority of CG100649 2 mg vs.
- Trial name
- NCT01765296
- Testing
- CG100649, Celecoxib
- Where
- 14 sites in South Korea
- Volunteers
- 362 people
- Sponsor
- CrystalGenomics, Inc.
Osteoarthritis, Hip
MONOVISC for Hip Joint Pain Relief Due to Osteoarthritis
Obtain real world, post market data to confirm the clinical improvement and safety in patients treated with a single injection of MONOVISC for the symptomatic relief of osteoarthritis in the hip joint.
- Trial name
- NCT04204083
- Testing
- Monovisc
- Where
- 4 sites in Czechia, Poland
- Volunteers
- 25 people
- Sponsor
- Anika Therapeutics, Inc.
Osteoarthritis, Knee, Osteoarthritis, Hip
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of…
- Trial name
- NCT02697773
- Testing
- Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
- Where
- 87 sites in United States, Canada and 1 more
- Volunteers
- 698 people
- Sponsor
- Pfizer
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.
- Trial name
- FACT OA2 (NCT03304379)
- Testing
- Fasinumab, Diclofenac, Celecoxib
- Where
- 71 sites in United States
- Volunteers
- 1,650 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis, Hip
Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip Joint
This Trial will obtain clinical data to support an expanded indication for a single injection of Cingal used for the symptomatic relief of osteoarthritis in the hip joint.
- Trial name
- NCT04640298
- Testing
- Cingal
- Where
- 4 sites in Czechia, Poland
- Volunteers
- 25 people
- Sponsor
- Anika Therapeutics, Inc.
Osteoarthritis
Effect of Structured Info and Adapted Exercise in OA
Physical activity level is measured at baseline and after 3 and 12 months after structured information and individually adapted exercise for patients with osteoarthritis in hip or knee.
- Trial name
- NCT02022566
- Testing
- A supported self management of osteoarthritis program
- Where
- Sweden
- Volunteers
- 317 people
- Sponsor
- Lund University
Osteo Arthritis Knee, Osteoarthritis, Hip
Development of an Osteoarthritis (OA) Care Plan to Improve Process and Quality of OA Treatment Decisions
Knee and hip osteoarthritis (OA) is the most common cause of disability in the U.S. and affects more than 60% of adults over 65 years.
- Trial name
- NCT03102580
- Testing
- OA Care Plan
- Where
- United States
- Volunteers
- 5,713 people
- Sponsor
- University of Massachusetts, Worcester
Osteoarthritis, Hip
Mini Stem Radiostereometric Analysis Study
The objectives of this study are to assess migration of the MIS Stem compared to the Synergy Hip System using Radiostereometric Analysis (RSA), and to assess the long-term safety and effectiveness of the study device.
- Trial name
- MISRSA (NCT01064531)
- Testing
- MIS Femoral Neck Stem implant
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Smith & Nephew, Inc.
Non-inflammatory Degenerative Joint Disease, Osteoarthritis
Ceramic-on-Ceramic (COC) 36mm Acetabular Bearing Insert Post Approval Study-New Subjects (COC36mmPAS)
This study is intended to gather short (Pre-operative to 4-years) and mid-term (5-years) information regarding the performance and safety of the commercially available 36mm CERAMAX® Ceramic on Ceramic Total Hip System from a…
- Conditions
- Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis, Post-Traumatic Osteoarthritis of Hip
- Trial name
- COC36mmPAS (NCT02096211)
- Testing
- COC 36mm
- Where
- 13 sites in United States, Canada
- Volunteers
- 172 people
- Sponsor
- DePuy Orthopaedics
Arthropathy of Hip Joint, Osteoarthritis, Hip
Opioid Free and Therapy Minimized Advantages Using HANA Table for Total Hip Arthroplasty
To prove that anterior approach total hip arthroplasty using the HANA table can be performed with little, if any, need for opioids using a combination of education, optimized pre op and post op pain protocols and optimized…
- Trial name
- NCT03790306
- Where
- United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- St. Elizabeth Medical Center, Utica, NY
Osteoarthritis
Tanezumab in Osteoarthritis of the Hip or Knee (2)
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
- Trial name
- NCT00863304
- Testing
- tanezumab 10 mg, tanezumab 5 mg, naproxen
- Where
- 95 sites in United States
- Volunteers
- 849 people
- Sponsor
- Pfizer
Arthritis
Aquatic Exercise and Efficacy Enhancement to Decrease Fall Risk in Older Adults With Hip Osteoarthritis
The objective of this project is to determine the effect of aquatic exercise and aquatic exercise combined with an education program on decreasing fall risk in older adults with hip osteoarthritis.
- Trial name
- NCT00289458
- Testing
- exercise, 2, Control
- Where
- Canada
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Hip Osteoarthritis, Knee Osteoarthritis
Backwards Walking Programme Following Hip and Knee Arthroplasty
Backwards walking has been shown to improve balance and walking in patients who have knee Osteoarthritis. It is not known if these benefits may also be seen after surgery in patients who have had a hip or knee replacement because…
- Conditions
- Hip Osteoarthritis, Knee Osteoarthritis, Hip Arthroplasty, Knee Arthroplasty
- Trial name
- NCT04247802
- Testing
- Backwards Walking (BW) programme, Usual Care
- Where
- 2 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Oxford University Hospitals NHS Trust
Osteoarthritis of the Hip
The Metaphyseal Hip Prosthesis - Total Hip
The purpose of this study is to analyze stability, safety and efficacy of the Metaphyseal Hip Prosthesis (MHP) compared to the Stanmore hip replacement.
- Trial name
- NCT01501955
- Testing
- Metaphyseal Hip Prosthesis, Stanmore
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Zimmer Biomet
Pain, Osteoarthritis, Hip
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee…
- Conditions
- Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT00980798
- Testing
- OROS hydromorphone HCl
- Where
- 12 sites in Czechia, Romania and 2 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag International NV
Osteoarthritis of the Knee or Hip
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
- Trial name
- FACT LTS & OA (NCT02683239)
- Testing
- Fasinumab
- Where
- 149 sites in United States, Bulgaria and 19 more
- Volunteers
- 5,331 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01141283
- Testing
- Buprenorphine transdermal patch
- Where
- 42 sites in United States
- Volunteers
- 290 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis
Extension Study Of Tanezumab In Osteoarthritis
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
- Trial name
- NCT00809783
- Testing
- tanezumab
- Where
- 226 sites in United States
- Volunteers
- 2,147 people
- Sponsor
- Pfizer
Hip Osteoarthritis, Primary Total Hip Arthroplasty
Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty
The purpose of this study is to learn if using a suprainguinal fascia iliaca (SIFI) injection technique (also called a "nerve block") that numbs the nerves going to the side and front of the upper leg will improve pain control…
- Conditions
- Hip Osteoarthritis, Primary Total Hip Arthroplasty, Pain
- Trial name
- NCT02933671
- Testing
- Suprainguinal fascia iliaca (SIFI) block, Ropivacaine, Saline
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe…
- Trial name
- NCT00313846
- Testing
- Buprenorphine transdermal patch
- Where
- 44 sites in United States
- Volunteers
- 529 people
- Sponsor
- Purdue Pharma LP